Friday May 29th
1:24 PM - 1:48 PM
Should We Use GnRH Agonists for Fertility Preservation?
Halle C. F. Moore, MD
Cleveland Clinic

5:10 PM - 5:30 PM
New Technologies and Platforms for Screening
Peter J. Mazzone, MD, MPH
Cleveland Clinic Respiratory Institute

Saturday May 30th
8:40 AM - 9:00 AM
Immunotherapy and Targeted Therapy in Brain Metastases: A Tailor-Made Approach
Manmeet Singh Ahluwalia, MD
Cleveland Clinic

Sunday, May 31st
12:00 PM - 12:15 PM
Case Considerations: Valuing Clinician Priorities
Neal J. Meropol, MD
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University

4:30-5:45
Discovery and Application of Targets in Clinical Research and Patient Care
Brian Rubin, MD
Cleveland Clinic

Mon, Jun 1
12:10 PM - 12:30 PM
Updates in Therapy and Clinical Trials in Small Cell Lung Cancer
Afshin Dowlati, MD
Case Western Reserve University

5:39 PM - 5:51 PM
Novel Approaches to Brain Metastases
Manmeet Singh Ahluwalia, MD
Cleveland Clinic

Tuesday June 2nd
10:25 AM - 10:45 AM
Of Nab-, Nano-, and Other Emerging Therapies in Pancreas Cancer: Do They Provide Good Value?
Neal J. Meropol, MD
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University

Posters/Abstracts
Can oncology readmissions be reduced? The Cleveland Clinic experience.
Abstract No: 6573
Poster Board Number: Board #130
Author(s): Alberto J. Montero, James Stevenson, Amy E. Guthrie, Carolyn Best, Lindsey Martin Goodman, Armida Parala, Ruth Lagman, Brian James Bolwell, Matt E. Kalaycio, Alok A. Khorana; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic, Cleveland Heights, OH; Cleveland Clinic Taussig Cancer Center, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute,
Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab [TCH-P] in non-metastatic HER2+ breast cancer: The Cleveland Clinic experience.

Abstract No: 531
Poster Board Number: Board #19
Author(s): Shruti Rakesh Tiwari, Benjamin Calhoun, Jame Abraham, G. Thomas Budd, Halle C. F. Moore, Alicia Fanning, Stephanie Valente, Robyn Stewart, Steven Ware Andresen, Susan B. LeGrand, Joseph P. Crowe, Andrea Dawson, Jordi Rowe, Christine Booth, Stephen R. Grobmyer, Alberto J. Montero; Cleveland Clinic Foundation, Shaker Heights, OH; Carolinas Pathology Group, Carolinas Medical Center, Charlotte, NC; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Fndtn, Shaker Heights, OH; Cleveland Clinic Fndtn, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland clinic foundation, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Fndtn, Shaker Heights, OH; Cleveland Clinic Fndtn, Cleveland, OH; Cleveland clinic, Cleveland, OH

Clinical implications of repeat tumor biopsy (RTB) in patients (pts) with advanced lung cancer (LC): The Cleveland Clinic (CC) experience.

Abstract No: 8077
Poster Board Number: Board #401
Author(s): Eberechi Sandra Agwa, Francisco Almeida, Abdo Haddad, Bruno R. Bastos, Roy Lee, Xuefei Jia, Patrick Ma; Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Respiratory Institute, Cleveland, OH; Fairview Hospital,Cleveland Clinic, Cleveland, OH; Cleveland Clinic Florida, Weston, FL; Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Mary Babb Randolph Cancer Center (MBRCC), West Virginia University, Morgantown, WV

Impact of a Stage IV NSCLC care pathway on front-line (FL) and maintenance (M) chemotherapy use at the Cleveland Clinic Taussig Cancer Institute (TCI).

Abstract No: 6609
Poster Board Number: Board #166
Author(s): Marc A. Shapiro, James Stevenson, Emily Van Wagoner, Katherine Glass, Chad W Cummings, Nathan A. Pennell, Patrick C. Ma, Vamsidhar Velcheti, Bruno R. Bastos, Brian James Bolwell, Abdo Haddad; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Taussig Cancer Inst, Highland Heights, OH; Cleveland Clinic Florida, Weston, FL; Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Fairview Hospital,Cleveland Clinic, Cleveland, OH

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A
Effect of improving guideline-based prophylactic growth factor (pGCSF) use with chemotherapy (CT) on the risk of febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients (pts): A Cleveland Clinic Taussig Cancer Institute (TCI) Quality Improvement (QI) Project.

Abstract No: 6565
Poster Board Number: Board #122
Author(s): Lindsey Martin Goodman, Machelle Moeller, Carole Kathleen Dalby, Abdel Azzouqa, Amy E. Guthrie, Marc A. Earl, Vamsidhar Velcheti, Marc A. Shapiro, Nathan A. Pennell, James Stevenson; Cleveland Clinic, Cleveland Heights, OH; Cleveland Clinic Foundation, Cleveland, OH; Dana Farber Cancer Inst, Boston, MA; Department of Pharmacy, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.

Abstract No: 8584
Poster Board Number: Board #402
Author(s): Frederic J. Reu, Dale Grabowski, Reda Z. Mahfouz, Hillard M. Lazarus, Robert M. Dean, Beth Faiman, Janice Reed, Mary Ann Karam, Kimberly Hamilton, Sherry Fada, Matt E. Kalaycio, Jason Neil Valent, Christy Joy Samaras, Ronald M. Sobeck, Linda McCowen, Jamie Elberson, Hien Liu, Yogen Saunthararajah, Yap Chew, Mitchell R. Smith; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Taussig Cancer Inst, Cleveland, OH; University Hosp of Cleveland, Cleveland, OH; Leukemia Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Eastlake, OH; Taussig Cancer Ctr, Chagrin Falls, OH; Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, Cleveland, OH; Zymo Research, Irvine, CA

Time: Sunday May 31, 8:00 AM to 11:30 AM
Location: S Hall A

Prospective clinical study of precision oncology in solid tumors.

Abstract No: 6585
Poster Board Number: Board #142
Author(s): Davendra Sohal, Brian I. Rini, Alok A. Khorana, Robert Dreicer, Jame Abraham, Gary Procop, Yogen Saunthararajah, Nathan A. Pennell, James Stevenson, Robert James Pelley, Bassam N. Estfan, Dale Randall Shepard, Pauline Funchain, David J. Adelstein, Brian James Bolwell; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; University of Virginia School of Medicine, Charlottesville, VA; UIC, Chicago, IL; Cleveland Clinic Foundation, Cleveland, OH; Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

Graded prognostic assessment index for colorectal cancer with brain metastases.

Abstract No: 2049
Poster Board Number: Board #38
Author(s): Vidhya Karivedu, Vyshak Alva Venur, Iullia Kim, Samuel T. Chao, John H. Suh, Davendra Sohal, Alok A. Khorana, Xuefei Jia, Manmeet Singh Ahluwalia; Fairview Hospital Cleveland Clinic, Cleveland, OH; Fairview Hospital, Cleveland Clinic, Cleveland, OH; Fairview Hospital Cleveland Clinic Hospital, Cleveland, OH; The Cleveland Clinic, University Hts, OH; Cleveland Clinic, Cleveland, OH; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A
The role of salvage radiation in recurrent glioblastoma after bevacizumab failure.
Abstract No: 2048
Poster Board Number: Board #37
Author(s): Nehaw Sarmey, Samuel T. Chao, Erin Sennett Murphy, Jennifer S. Yu, David M. Peereboom, Glen Stevens, John H. Suh, Manmeet Singh Ahluwalia; Cleveland Clinic, Cleveland Heights, OH; The Cleveland Clinic, University Hts, OH; Cleveland Clinic Fndtn, University Hts, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic Fndtn Desk, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH
Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.
Abstract No: 5020
Poster Board Number: Board #12
Author(s): Jason W.D. Hearn, Ghada AbuAli, Cristina Magi-Galluzzi, Chandana A. Reddy, Kai-Hsiung Chang, Eric A. Klein, Nima Sharifi; Cleveland Clinic, Cleveland, OH; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Departments of Hematology and Oncology, Cancer Biology, and Urology, Taussig Cancer Institute and Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH
Time: Saturday May 30, 1:15 PM to 4:45 PM
Location: S Hall A

Phase II trial of dovitinib in recurrent glioblastoma.
Abstract No: 2050
Poster Board Number: Board #39
Author(s): Manmeet Singh Ahluwalia, Nikolaos Papadantonakis, Vyshak Alva Venur, Cathy Schilero, David M. Peereboom, Glen Stevens, Steven Rosenfeld, Michael A. Vogelbaum, Paul Elson, Andrew B. Nixon, Keith McCrae; Cleveland Clinic, Cleveland, OH; Fairview Hospital, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Fndtn Desk, Cleveland, OH; Cleveland Clinic Fndtn Desk, Cleveland, OH; Cleveland Clinic Brain Tumor I, Cleveland, OH; Duke University Medical Center, Durham, NC
Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

Hereditary implications of somatic tumor testing.
Abstract No: 1523
Poster Board Number: Board #347
Author(s): Pauline Funchain, Davendra Sohal, Alok A. Khorana, Jame Abraham, Nathan A. Pennell, Brian I. Rini, Robert Dreicer, Brian James Bolwell, Charis Eng; Cleveland Clinic, Cleveland, OH; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; University of Virginia School of Medicine, Charlottesville, VA; Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Fnd, Cleveland, OH
Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma.
Abstract No: 4562
Poster Board Number: Board #236
Author(s): Moshe Chaim Ornstein, Paul Elson, Jorge A. Garcia, Timothy D. Gilligan, Laura S. Wood, Kimberly D Allman, Allison Martin, Brian I. Rini; Cleveland Clinic Fndtn, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Shaker Heights, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A
Graded prognostic assessment (GPA) of HER2 positive breast cancer patients with brain metastases.

Abstract No: 589
Poster Board Number: Board #78
Author(s): Ming Chi, Vyshak Alva Venur, Alireza Mohammad Mohammadi, Samuel T. Chao, G. Thomas Budd, Alberto J. Montero, Halle C. F. Moore, Paul Elson, John H. Suh, Lilyana Angelov, Gene H. Barnett, Jame Abraham, Manmeet Singh Ahluwalia; Cleveland Clinic, Cleveland, OH; Fairview Hosp Cleveland Clinic Hosp, Cleveland, OH; The Cleveland Clinic, University Hts, OH; Cleveland Clinic Foundation, Cleveland, OH

Time: Saturday May 30, 8:00 AM to 11:30 AM
Location: S Hall A

Outcomes and prognostic factors in marginal zone lymphoma: Case comprehensive cancer center cumulative experience of 358 cases.

Abstract No: 8554
Poster Board Number: Board #372
Author(s): Adam Starr, PingFu Fu, Paolo Fabrizio Caimi, Erica Leigh Campagnaro, Brenda W. Cooper, Marcos J.G. De Lima, Hillard M. Lazarus, Stanton L. Gerson, Howard Meyerson, Deepa Jagadeesh, Mitchell Reed Smith, Robert M. Dean, Brad L. Pohlman, Brian Thomas Hill, Basem M. William; Case Western Reserve University, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Western Reserve University, and Case Comprehensive Cancer Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Western Reserve University, and Case Comprehensive Cancer Center, Cleveland, OH; University Hospitals Case Medical Center, Cleveland, OH; Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH; Cleveland Clinic, Cleveland, OH

Time: Sunday May 31, 8:00 AM to 11:30 AM
Location: S Hall A

Tumor infiltrating lymphocytes associated with brain metastasis in breast cancer.

Abstract No: 2059
Poster Board Number: Board #48
Author(s): Nicole Olivia Williams, Cheryl L. Thompson, Shikha Parsai, Vinay Varadan, Kristy Miskimen, Jill Barnholtz-Sloan, Paula Silverman, Shaveta Vinayak, Lisa R. Rogers, Andrew E. Sloan, Lyndsay Harris, Hannah L. Gilmore; University Hosp/Case Western Reserve Univ, Cleveland, OH; Case Western Reserve University School of Medicine, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University Hosps Case Medcl Ctr, Cleveland, OH; Department of Medicine, Hematology and Oncology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, OH; University Hosp of Cleveland, Cleveland, OH; Univ Hosp Case Medcl Ctr, Cleveland, OH; University Hosps Case Medcl Ctr, Beachwood, OH

Type: Poster Session
Time: Monday June 1, 1:15 PM to 4:45 PM

HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.

Abstract No: 5020
Poster Board Number: Board #12
Author(s): Jason W.D. Hearn, Ghada AbuAli, Cristina Magi-Galluzzi, Chandana A. Reddy, Kai-Hsiung Chang, Eric A. Klein, Nima Sharifi; Cleveland Clinic, Cleveland, OH; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH; Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH; Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Departments of Hematology and Oncology, Cancer Biology, and Urology, Taussig Cancer Institute and Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH

Time: Saturday May 30, 1:15 PM to 4:45 PM
Location: S Hall A
Graded prognostic assessment (GPA) of HER2 positive breast cancer patients with brain metastases.

Abstract No: 589
Poster Board Number: Board #78
Author(s): Ming Chi, Vyshak Alva Venur, Alireza Mohammad Mohammadi, Samuel T. Chao, G. Thomas Budd, Alberto J. Montero, Halle C. F. Moore, Paul Elson, John H. Suh, Lilyana Angelov, Gene H. Barnett, Jame Abraham, Manmeet Singh Ahluwalia; Cleveland Clinic, Cleveland, OH; Fairview Hosp Cleveland Clinic Hosp, Cleveland, OH; The Cleveland Clinic, University Hts, OH; Cleveland Clinic Foundation, Cleveland, OH

Time: Saturday May 30, 8:00 AM to 11:30 AM
Location: S Hall A

Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma.

Abstract No: 4562
Poster Board Number: Board #236
Author(s): Moshe Chaim Ornstein, Paul Elson, Jorge A. Garcia, Timothy D. Gilligan, Laura S. Wood, Kimberly D Allman, Allison Martin, Brian I. Rini; Cleveland Clinic Fdn, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Shaker Heights, OH; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Type: Poster Session
Time: Monday June 1, 1:15 PM to 4:45 PM

Identification of RICTOR amplification as a recurrent and potentially actionable alteration in small cell lung cancer patients.

Abstract No: 7576
Poster Board Number: Board #324
Author(s): Snehal Dabir, Gary Wildey, Karen McColl, Pingfu Fu, Yan Feng, Afshin Dowlati; Case Western Reserve University, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University Hosp Case Western Reserve Univ, Broadview Heights, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

Type: Poster Session
Time: Monday June 1, 8:00 AM to 11:30 AM

Phase I clinical trial of temozolomide and methoxyamine (TRC-102) in patients with advanced solid tumors.

Abstract No: 2558
Poster Board Number: Board #274
Author(s): Jennifer Rachel Eads, Smitha S. Krishnamurthi, Joel N. Saltzman, Neal J. Meropol, Joseph A. Bokar, Joseph Gibbons, Henry B. Koon, Neelesh Sharma, Panayiotis Savvides, John Pink, Yan Xu, Jan Hendrik Beumer, Pingfu Fu, Kristi Beatty, Donna Kane, Mary Beth Rodal, Julianne Czalkiewicz, John Riendeau, Stanton L. Gerson, Afshin Dowlati; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH; The James Ohio State University Comprehensive Cancer Center, Columbus, OH

Time: Saturday May 30, 8:00 AM to 11:30 AM
Location: S Hall A
TOP2A-based prognostication in triple negative breast cancer and correlation with basal phenotype.
Abstract No: 1098
Poster Board Number: Board #212
Author(s): Benjamin C. Calhoun, Christopher Lanigan, Brian Rubin, Karen C Mrazek, Gabriela Rosa, Michael Barnes, Sherry Dean, Bonnie LaFleur; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Pathology and Laboratory Medicine Institute, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Roche Diagnostics, Mountain View, CA; Roche Diagnostics, Tucson, AZ
Time: Saturday May 30, 8:00 AM to 11:30 AM
Location: S Hall A

Clinical correlation of genomic mutations in small cell lung cancer.
Abstract No: 7575
Poster Board Number: Board #323
Citation: J Clin Oncol 33, 2015 (suppl; abstr 7575)
Author(s): Afshin Dowlati, Pingfu Fu, Mary Beth Lipka, Gary Wildey; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH
Time: Monday June 1, 8:00 AM to 11:30 AM
Location: S Hall A

Association of tumor infiltrating lymphocytes (TILs) with pathologic response in baseline and post-brief exposure HER2+ breast cancer biopsies from BrUOG-211B.
Abstract No: 619
Poster Board Number: Board #109
Author(s): Stefanie Avril, Vinay Varadan, Kristy Miskimen, Jahnavi Gollamudi, Maysa M. Abu-Khalaf, George Somlo, William M. Sikov, Lyndsay Harris, Shaveta Vinayak; Department of Pathology, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH; Department of Medicine, Hematology and Oncology, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, OH; Brown University Oncology Research Group (BrUOG), Brown University, Providence, RI; Department of Medicine, Hematology and Oncology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, OH
Time: Saturday May 30, 8:00 AM to 11:30 AM
Location: S Hall A

CoaGlio IV Trial: Randomized, controlled, triple-blind, multinational phase III study of adjuvant prophylactic anticoagulation in patients with glioblastoma WHO IV.
Abstract No: TPS2079
Poster Board Number: Board #67b
Author(s): Susanne Antje Kuhn, Christine Marosi, Ingrid Pabinger, Lars Bullinger, Roland Goldbrunner, Alok A. Khorana, Manmeet Singh Ahluwalia, Frederick R. Rickles, Gary H. Lyman, Peter Vajkoczy; Hospital Ernst von Bergmann, Potsdam, Germany; University of Vienna, Wien, Austria; Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany; Department of Neurosurgery, University of Cologne and Center of Integrated Oncology Cologne/Bonn, Cologne, Germany; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic, Cleveland, OH; George Washington University, Washington, DC; Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Neurosurgery, Charite Universitaetsmedizin Berlin, Berlin, Germany
Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A
APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.
Abstract No: 11047
Poster Board Number: Board #260
Author(s): Aziz Nazha, Bartlomiej Przychodzen, Hideki Makishima, Mayur Narkhede, Matt E. Kalaycio, David James Seastone, Hetty Carraway, Aaron Thomas Gerds, Sudipto Mukherjee, Anjali S. Advani, Jennifer Carew, Mikkael A. Sekeres, Jaroslaw P. Maciejewski; Leukemia Program, Department of Hematology and Oncology, Cleveland Clinic, Cleveland, OH; Translational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH
Time: Sunday May 31, 8:00 AM to 11:30 AM
Location: S Hall A

SLC1A5 to predict outcome with chemotherapy in early triple-negative breast cancer.
Abstract No: 2530
Poster Board Number: Board #246
Author(s): Anna Maria Affan, Vinay Varadan, Hannah L. Gilmore, Kristy Miskimen, Young Joo Jeon, Shikha Parsai, Ze'ev Ronai, Lyndsay Harris; St Vincent Charity Medical Center, Cleveland, OH; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH; University Hosps Case Medcl Ctr, Beachwood, OH; Case Western Reserve University, Cleveland, OH; Sanforn Burnham Medical Research Institute, San Diego, CA; Sanford Burnham Medical Research Institute, San Diego, CA
Time: Saturday May 30, 8:00 AM to 11:30 AM
Location: S Hall A

Effect of current smoking on risk of triple negative breast cancer.
Abstract No: 1592
Poster Board Number: Board #416
Author(s): Dhivya Prabhakar, Lyndsay Harris, Cheryl L. Thompson; University Hospital/Case Western Reserve University, Cleveland, OH; Department of Medicine, Hematology and Oncology, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, OH; Case Western Reserve University, Cleveland, OH
Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

Brain Tumor Trials Collaborative Bayesian Adaptive Randomized Phase II trial of bevacizumab plus vorinostat versus bevacizumab alone in adults with recurrent glioblastoma (BTTC-1102).
Abstract No: 2012
Poster Board Number: Board #1
Author(s): Vinay K. Puduvalli, Jing Wu, Ying Yuan, Terri S. Armstrong, Morris D. Groves, Jeffrey J. Raizer, Pierre Giglio, Howard Colman, David M. Peereboom, Tobias Walbert, Nicholas George Averopoulos, Fabio Massaiti Iwamoto, Marc C. Chamberlain, Nina Paleologos, Karen L. Fink, Ryan Merrell, W. K. Alfred Yung, Mark R. Gilbert; Ohio State University Comprehensive Cancer Center, Columbus, OH; UNC Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, NC; The University of Texas MD Anderson Cancer Center, Houston, TX; The University of Texas Health Science Center School of Nursing, Houston, TX; Texas Onc/US Onc - Austin Brain Tumor Ctr, Austin, TX; Lurie Comp Cancer Ctr of Northwestern Univ, Chicago, IL; The Ohio State University Wexner Medical Center, Columbus, OH; Hunstman Cancer Inst Univ of Utah, Salt Lake City, UT; Cleveland Clinic Fndtn Desk, Cleveland, OH; Henry Ford Hosp Detroit, Huntington Woods, MI; UF Health Cancer Center Orlando, Orlando, FL; Columbia University Medical Center, New York, NY; University of Washington, Seattle, WA; Rush University, Chicago, IL; Baylor Research Institute, Dallas, TX; NorthShore University Health System, Evanston, IL
Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A
Contemporary national trends of prostate cancer screening among privately insured patients in the United States.

Abstract No: 5065
Poster Board Number: Board #59
Author(s): Simon P. Kim, Jeffrey Karnes, Cary Philip Gross, Neal J. Meropol, Holly K. Van Houten, Robert Abouassaly, Nilay D. Shah; Yale University, New Haven, CT; The Mayo Clinic, Rochester, MN; Yale School of Medicine, New Haven, CT; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Mayo Clinic, Rochester, MN; Urological Institute, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH; Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN

Time: Saturday May 30, 1:15 PM to 4:45 PM
Location: S Hall A

A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes.

Abstract No: TPS4575
Poster Board Number: Board #246b
Author(s): Noah M. Hahn, Joel Picus, Richard Martin Bambury, Sumanta Kumar Pal, Lowell L. Hart, Petros Grivas, Matthew I. Milowsky, Ajjai Shivaram Alva, Guru Sonpavde, Amir Mortazavi, Joaquim Bellmunt, Elizabeth A. Guancial, Sumati Gupta, Richard C. Chao, Mary A. Collier, James Christensen, Iisan Chen, Jonathan E. Rosenberg; Johns Hopkins Kimmel Cancer Center, Baltimore, MD; Division of Oncology, Washington University in St. Louis, St. Louis, MO; Memorial Sloan Kettering Cancer Center, New York, NY; City of Hope, Duarte, CA; Florida Cancer Specialists, Fort Myers, FL; Cleveland Clinic, Cleveland, OH; UNC Chapel Hill, Chapel Hill, NC; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; Arthur G. James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Wilmot Cancer Institute, University of Rochester, Rochester, NY; Huntsman Cancer Inst, Fruit Heights, UT; Mirati Therapeutics Inc., San Diego, CA

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

Is rituximab sub-optimally dosed in indolent B cell lymphoma?

Abstract No: 8567
Poster Board Number: Board #385
Author(s): Yazeed Sawalha, Basel Rouphail, Xuefei Jia, Robert M. Dean, Brian Thomas Hill, Deepa Jagadeesh, Brad L. Pohlman, Paul Elson, Mitchell Reed Smith; Cleveland Clinic, Cleveland, OH

Time: Sunday May 31, 8:00 AM to 11:30 AM
Location: S Hall A

The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC).

Abstract No: TPS4583
Poster Board Number: Board #250b
Author(s): Martin Henner Voss, Elizabeth R. Plimack, Brian I. Rini, Michael B. Atkins, Robert Alter, Rupal Satish Bhatt, J. Thaddeus Beck, Musa Mutyaba, Kristen M. Pappas, Dawn Wilson, Xiaosha Zhang, Matthew L. Sherman, Shuchi Sumant Pandya; Memorial Sloan Kettering Cancer Center, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Lombardi Comprehensive Cancer Center, Washington, DC; John Theurer Cancer Center, Hackensack, NJ; Beth Israel Deaconess Medical Center, Boston, MA; Highlands Oncology Group, Fayetteville, AR; Acceleron Pharma, Cambridge, MA

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A
Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC).

Abstract No: 4566
Poster Board Number: Board #240
Author(s): Rosa Nadal, Asim Amin, Daniel M. Geynisman, Martin Henner Voss, Matthew Weinstock, Jaime Doyle, Zhe Zhang, Antonio Viudez, Elizabeth R. Plimack, David F. McDermott, Robert Motzer, Brian I. Rini, Hans J. Hammers; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Levine Cancer Institute, Charlotte, NC; Fox Chase Cancer Center, Philadelphia, PA; Memorial Sloan Kettering Cancer Center, New York, NY; BIDMC, Cambridge, MA; Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA; Johns Hopkins Kimmel Cancer Center, Baltimore, MD; Beth Israel Deaconess Medical Center, Boston, MA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

**Time:** Monday June 1, 1:15 PM to 4:45 PM

**Location:** S Hall A


Abstract No: TPS4577
Poster Board Number: Board #247b
Author(s): Toni K. Choueiri, Noah M. Hahn, Ajai Shivaram Alva, Richard C. Lauer, Robert Dreicer, Joel Picus, Roberto Pili, Arjun Vasant Balar, Guru Sonpavde, Jean H. Hoffman-Censits, Elizabeth A. Guancial, Robert Alter, Meredith M. Regan, Cindy Jacobs, Patricia S. Stewart, Sumantha Kumar Pal, Jonathan E. Rosenberg; Dana-Farber Cancer Institute, Boston, MA; The Johns Hopkins Medical Institutions, Indianapolis, IN; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI; University of New Mexico Cancer Center, Albuquerque, NM; Cleveland Clinic, Cleveland, OH; Division of Oncology, Washington University in St. Louis, St. Louis, MO; Roswell Park Cancer Institute, Buffalo, NY; Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; Wilmot Cancer Institute, University of Rochester, Rochester, NY; John Theurer Cancer Center, Hackensack, NJ; Dana Farber Cancer Inst, Boston, MA; OncoGenex Pharmaceuticals, Inc., Bothell, WA; OncoGenex Pharmaceuticals Inc., Bothell, WA; City of Hope, Duarte, CA; Memorial Sloan Kettering Cancer Center, New York, NY

**Time:** Monday June 1, 1:15 PM to 4:45 PM

**Location:** S Hall A

A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain.

Abstract No: TPS9080
Poster Board Number: Board #322b
Author(s): Kim Allyson Margolin, Hussein Abdul-Hassan Tawbi, Marc S. Ernstoff, F. Stephen Hodi, David F. McDermott, Robin Edwards, Alexandre Avila, Michael B. Atkins; Stanford University Medical Center and the Cytokine Working Group (CWG), Stanford, CA; University of Pittsburgh Cancer Inst, Pittsburgh, PA; Cleveland Clinic Foundation and the Cytokine Working Group (CWG), Cleveland, OH; Dana-Farber Cancer Institute and the Cytokine Working Group (CWG), Boston, MA; Beth Israel Deaconess Medical Center and the Cytokine Working Group (CWG), Boston, MA; Bristol-Myers Squibb, Plainsboro, NJ; Georgetown-Lombardi Comprehensive Cancer Center and the Cytokine Working Group (CWG), Washington, DC

**Time:** Monday June 1, 1:15 PM to 4:45 PM

**Location:** S Hall A
The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC).

Abstract No: 4567
Poster Board Number: Board #241
Author(s): Martin Henner Voss, Elizabeth R. Plimack, Brian I. Rini, Michael B. Atkins, Robert Alter, Rupal Satish Bhatt, J. Thaddeus Beck, Musa Mutyaba, Kristen M. Pappas, Dawn Wilson, Xiaoshia Zhang, Matthew L. Sherman, Shuchi Sumant Pandya; Memorial Sloan Kettering Cancer Center, New York, NY; Fox Chase Cancer Center, Philadelphia, PA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Lombardi Comprehensive Cancer Center, Washington, DC; John Theurer Cancer Center, Hackensack, NJ; Beth Israel Deaconess Medical Center, Boston, MA; Highlands Oncology Group, Fayetteville, AR; Acceleron Pharma, Cambridge, MA

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).

Abstract No: 4553
Poster Board Number: Board #227
Author(s): Elizabeth R. Plimack, Hans J. Hammers, Brian I. Rini, David F. McDermott, Bruce Redman, Timothy Kuzel, Michael Roger Harrison, Ulka N. Vaishampayan, Harry A. Drabkin, Saby George, Theodore F. Logan, Kim Allyson Margolin, Li-an Xu, Ian Waxman, Robert Motzer; Fox Chase Cancer Center, Philadelphia, PA; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Beth Israel Deaconess Medical Center, Boston, MA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Northwestern University Feinberg School of Medicine, Chicago, IL; Duke University Medical Center, Durham, NC; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Medical University of South Carolina, Charleston, SC; Roswell Park Cancer Institute, Buffalo, NY; Indiana University Simon Cancer Center, Indianapolis, IN; Seattle Cancer Care Alliance, Seattle, WA; Bristol-Myers Squibb, Princeton, NJ; Memorial Sloan Kettering Cancer Center, New York, NY

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.

Abstract No: 2036
Poster Board Number: Board #25
Author(s): Terri S. Armstrong, Patrick Y. Wen, David A. Reardon, Surasak Phuphanich, Robert Aiken, Joseph C. Landolfi, William T. Curry, Jay-Jiguang Zhu, Michael J. Glantz, David M. Peereboom, James Markert, Renato V. LaRocca, Donald O'Rourke, Karen L. Fink, Lyndon J. Kim, Michael L. Gruber, Glenn Jay Lesser, Edward Pan, Santosh Kesari, John Yu; The University of Texas Health Science Center School of Nursing, Houston, TX; Dana-Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Center Institute and Harvard School of Medicine, Boston, MA; Cedars-Sinai Med Ctr, Los Angeles, CA; Rush University Medical Center, Chicago, IL; NJ Neurosci Inst At JFK Medcl Ctr, Edison, NJ; Massachusetts General Hospital, Boston, MA; The University of Texas Medical School at Houston, Houston, TX; Penn State - Milton S Hershey Medc Ctr, Hinsdale, MA; Cleveland Clinic Fndtn Desk, Cleveland, OH; The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; Norton Cancer Inst, Louisville, KY; University of Pennsylvania, Philadelphia, PA; Baylor Research Institute, Dallas, TX; Thomas Jefferson University, Philadelphia, PA; NYU Clinical Cancer Ctr, Englewood, NJ; Wake Forest University, Winston Salem, NC; The University of Texas Southwestern Medical Center, Dallas, TX; UC San Diego, La Jolla, CA

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A
Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.

Abstract No: 4519
Poster Board Number: Board #189
Author(s): Andre Poisl Fay, David J. Kwiatkowski, Kathryn P. Gray, Aaron Thorner, Brian I. Rini, Neeraj Agarwal, Thai Huu Ho, Jiaxi Song, Pablo M Barrios, Laurence Albiges, Eliezer Mendel Van Allen, Katherine Maragaret Krajewski, Camillo Porta, Sumanta Kumar Pal, Joaquim Bellmunt, David F. McDermott, Daniel Yick Chin Heng, Sabina Signoretti, Toni K. Choueiri; Oncology Service and Oncology Research Unit, HSL/PUCRS, Porto Alegre, Brazil; Dana-Farber Cancer Institute, Boston, MA; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Mayo Clinic, Scottsdale, AZ, Scottsdale, AZ; Brigham and Women's Hospital, Boston, MA; PUCRS School of Medicine, Porto Alegre, Brazil; Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Dana Farber Cancer Inst, Boston, MA; IRCCS San Matteo University Hospital Foundation, Pavia, Italy; City of Hope, Duarte, CA; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada; Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).

Abstract No: 4507
Author(s): Andrew J. Armstrong, Samuel Broderick, Tim Eisen, Walter Michael Stadler, Robert J. Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian K. Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa M. Pickering, Christopher W. Ryan, Andrew Protheroe, Christine M. Lusk, Sadie Oberg, Susan Halabi, Daniel J. George; Duke Cancer Institute, Duke University, Durham, NC; Duke Clinical Research Institute, Durham, NC; University of Cambridge, Cambridge, United Kingdom; University of Chicago, Chicago, IL; The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Cleveland Clinic, Cleveland, OH; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Division of Oncology, Washington University in St. Louis, St. Louis, MO; The Christie NHS Foundation Trust, Manchester, United Kingdom; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; BC Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Vanderbilt University Medical Center, Nashville, TN; St Georges Healthcare Trust, London, United Kingdom; Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR; University of Oxford Medical Oncology Department, Oxford, United Kingdom; inVentiv Health Clinical, Pearland, TX; Inventiv Health Clinical, Durham, NC; Duke University Medical Center, Durham, NC; Duke Cancer Institute, Durham, NC

Time: Monday June 1, 9:45 AM to 12:45 PM
Location: E Arie Crown Theater
Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

Abstract No: 4516
Poster Board Number: Board #186
Author(s): Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Brian I. Rini, David F. McDermott, Marc Ernstoff, Martin Henner Voss, Padmanee Sharma, Sumanta Kumar Pal, Albiruni R. A. Razak, Christian K. Kollmannsberger, Daniel Yick Chin Heng, Jennifer L. Spratlin, Yun Shen, Paul Gagnier, Asim Amin; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Fox Chase Cancer Center, Philadelphia, PA; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Beth Israel Deaconess Medical Center, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; The University of Texas MD Anderson Cancer Center, Houston, TX; City of Hope Comprehensive Cancer Center, Duarte, CA; Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; British Columbia Cancer Agency, Vancouver, BC, Canada; Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada; Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; Bristol-Myers Squibb, Princeton, NJ; Levine Cancer Institute, Charlotte, NC

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma.

Abstract No: 4545
Poster Board Number: Board #218
Author(s): Brian I. Rini, Yoshihiko Tomita, Bohuslav Melichar, Takeshi Ueda, Viktor Grünwald, Mayer N. Fishman, Hirotugu Uemura, Mototsugu Oya, A H. Bair, Glen Andrews, Dmitri Pavlov, Eric Jonasch; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Department of Urology, Yamagata University School of Medicine, Yamagata, Japan; Palacký University Medical School & Teaching Hospital, Olomouc, Czech Republic; Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan; Department of Hematology, Hemostasis, Oncology and Stem cell transplantation, Hannover Medical School, Hannover, Germany; Moffitt Cancer Center, Tampa, FL; Department of Urology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan; Keio University, Shinjuku-Ku, Japan; Pfizer Oncology, San Diego, CA; Pfizer Clinical Development, New York, NY; The University of Texas MD Anderson Cancer Center, Houston, TX

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

Abstract No: 4548
Poster Board Number: Board #221
Author(s): Meta Diekstra, Jesse J Swen, Epie Boven, Daniel E. Castellano, Hans Gelderblom, Ron H.J. Mathijssen, Cristina Rodriguez-Anton, Jesús García-Donas, Brian I. Rini, Henk-jan Guchelaar; Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands; VU University Medical Center, Amsterdam, Netherlands; Hospital Universitario 12 de Octubre, Madrid, Spain; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands; Spanish National Cancer Research Center, Madrid, Spain; Centro Integral Oncológico Clara Campal, Madrid, Spain; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, Netherlands

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A
Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC).

Abstract No: 4558
Poster Board Number: Board #232
Author(s): Haoran Li, Toni K. Choueiri, Connor Wells, Neeraj Agarwal, Frede Donskov, Jae-Lyun Lee, Reuben James Broom, Takeshi Yuasa, Brian I. Rini, Sumanta Kumar Pal, Lori Wood, D. Scott Ernst, Christian K. Kollmannsberger, Ulka N. Vaishampayan, Sun Young Rha, Georg A. Bjarnason, Jennifer J. Knox, Sadia Saleem, Benoit Beuselinck, Daniel Yick Chin Heng; Tom Baker Cancer Center, Calgary, AB, Canada; Dana-Farber Cancer Institute, Boston, MA; Tom Baker Cancer Centre, Calgary, AB, Canada; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Auckland City Hospital, Auckland, New Zealand; Department of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope, Duarte, CA; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada; London Regional Cancer Centre, London, ON, Canada; BC Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Karmanos Cancer Institute, Wayne State University, Detroit, MI; Yonsei University College of Medicine, Seoul, South Korea; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada; The University of Texas Southwestern Medical Center, Dallas, TX; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

Results of a randomized, global, multi-center study of whole-brain radiation therapy (WBRT) plus veliparib or placebo in patients (pts) with brain metastases (BM) from non-small cell lung cancer (NSCLC).

Abstract No: 2021
Poster Board Number: Board #10
Author(s): Pierre Chabot, Jeong-Seon Ryu, Vera Gorbunova, Cristobal Belda, David Ball, Ebenezer A. Kio, Minesh Mehta, Katherine Papp, Qin Qin, Jane Qian, Kyle D. Holen, Vincent L. Giranda, John H. Suh; Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada; Inha University Hospital, Incheon, South Korea; N.N.Blokhin Russian Cancer Research Center, Moscow, Russia; Centro Integral Oncológico Clara Campal, University Hospital MN Sanchinarro, Madrid, Spain; Peter MacCallum Cancer Centre, East Melbourne, Australia; Goshen Center for Cancer Care, Goshen, IN; University of Maryland, Baltimore, MD; AbbVie, North Chicago, IL; Cleveland Clinic, Cleveland, OH

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A
Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study.

Abstract No: 9004
Author(s): F. Stephen Hodi, Michael Andrew Postow, Jason Alan Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolas Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser F. Shaheen, Marc S. Ernstoff, David R. Minor, April Salama, Matthew Hiram Taylor, Patrick Alexander Ott, Christine E. Horak, Paul Gagnier, Jedd D. Wolchok; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; J. Graham Brown Cancer Center, University of Louisville, Louisville, KY; New York University, Perlmutter Cancer Center, New York, NY; Gustave Roussy and Paris-Sud University, Villejuif-Paris-Sud, France; Huntsman Cancer Institute, Salt Lake City, UT; Beth Israel Deaconess Medical Center, Boston, MA; Washington University, St. Louis, MO; Institut Universitaire du Cancer, Toulouse, France; NCORP of the Carolinas, Greenville, SC; St. Luke’s Cancer Center, Bethlehem, PA; University of New Mexico, Albuquerque, NM; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH; California Pacific Melanoma Center, San Francisco, CA; Duke University, Durham, NC; Oregon Health & Science University, Portland, OR; Bristol-Myers Squibb, Princeton, NJ; Bristol-Myers Squibb, Wallingford, CT

Time: Saturday May 30, 1:15 PM to 4:15 PM
Location: E354b

Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: The CATCH study.

Abstract No: 9621
Poster Board Number: Board #280
Author(s): Alok A. Khorana, Rupert Bauersachs, Pieter W Kamphuisen, Guy Meyer, Mette S. Janas, Mikala F. Jarner, Agnes Y. Lee, CATCH Investigators; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH; Department of Vascular Medicine, Darmstadt Hospital, Darmstadt, Germany; Department of Vascular Medicine, University Medical Center Groningen, Groningen, Netherlands; Respiratory Unit, Georges Pompidou European Hospital, Paris, France; LEO Pharma, Ballerup, Denmark; Division of Hematology, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada

Time: Saturday May 30, 1:15 PM to 4:45 PM
Location: S Hall A

METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC).

Abstract No: TPS1110
Poster Board Number: Board #219a
Author(s): Denise A. Yardley, Michelle E. Melisko, Andres Forero, Brooke R. Daniel, Alberto J. Montero, Troy H. Guthrie, Vikki A. Canfield, Catherine Angela Oakman, Helen K. Chew, Cristiano Ferrario, Gena H. Volas-Redd, Robyn R. Young, Norah Lynn Henry, Lynn Aneiro, Yi He, Christopher D. Turner, Thomas A. Davis, Linda T. Vahdat, The METRIC Study Group; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; UC San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Alabama at Birmingham, Birmingham, AL; Chattanooga Oncology Hematology Associates, Chattanooga, TN; Cleveland Clinic, Cleveland, OH; Baptist Cancer Inst, Jacksonville, FL; Mercy Clinic Oklahoma Communities, Inc., Oklahoma City, OK; Western Health, Footscray, Australia; UC Davis Medical Center, Sacramento, CA; Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada; Georgia Cancer Specialists affiliated with Northside Hospital Cancer Institute, Atlanta, GA; Oncology Hematology Consultants PA, Fort Worth, TX; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Cellnex Therapeutics, Inc., Hampton, NJ; Weill Cornell Medical College, New York, NY

Time: Saturday May 30, 8:00 AM to 11:30 AM
Location: S Hall A
A single-arm, open-label, phase II study to evaluate the safety of vemurafenib (VEM) followed by ipilimumab (IPI) in BRAF V600-mutated metastatic melanoma (MM).

Abstract No: 9032
Poster Board Number: Board #275

Author(s): Asim Amin, David H. Lawson, April K. Salama, Henry B. Koon, Troy H. Guthrie, Sajeve Samuel Thomas, Steven O’Day, Montaser F. Shaheen, Bin Zhang, Stephen Francis, F. Stephen Hodi; Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC; Winship Cancer Institute of Emory University, Atlanta, GA; Duke University Medical Center, Durham, NC; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Baptist Cancer Institute, Jacksonville, FL; MD Anderson Cancer Center Orlando, Orlando, FL; Los Angeles Skin Cancer Institute at Beverly Hills Cancer Center, Beverly Hills, CA; University of New Mexico Cancer Center, Albuquerque, NM; Bristol-Myers Squibb, Wallingford, NJ; Bristol-Myers Squibb, Braine-l’Alleud, Belgium; Dana-Farber Cancer Institute, Boston, MA

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A

Phase I study of MEDI0639 in patients with advanced solid tumors.

Abstract No: 3024
Poster Board Number: Board #350

Author(s): Gerald Steven Falchook, Afshin Dowlati, Aung Naing, Matthew Joseph Gribbin, David William Jenkins, Linda L Chang, Dominic W Lai, David C. Smith; Sarah Cannon Research Institute at HealthONE, Denver, CO; University Hospital, Cleveland, OH; Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX; Human Genome Sciences, Gaithersburg, MD; MedImmune, Gaithersburg, MD; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

Time: Saturday May 30, 8:00 AM to 11:30 AM
Location: S Hall A

HLA-DRB1*07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO.

Abstract No: 617
Poster Board Number: Board #107

Author(s): Colin F. Spraggs, Laura Rae Parham, Liling Warren, Lisa Simone Williams, Linda P Briley, Dana Fraser, Zefei Jiang, Zeba Aziz, Zhongsheng Tong, Shun Devan Moodley, Ajay O. Mehta, Nicola Jackson, Julie Byrne, Michael Andersson, Masakazu Toi, Lyndsay Harris, Julie Gralow, Rocco Crescenzo, Alison A. Armour; GlaxoSmithKline, Stevenage, United Kingdom; GlaxoSmithKline, Raleigh-Durham, NC; GlaxoSmithKline, London, United Kingdom; Hospital Affiliated to Academy Military Medical Science, Beijing, China; Hameed Latif Hospital, Lahore, Pakistan; Tianjin Cancer Hospital, Tianjin, China; University of Witwatersrand, Parktown, South Africa; Central India Cancer Research Institute, Nagpur, India; GlaxoSmithKline, Collegeville, PA; Rigshospitalet, Copenhagen, Denmark; Kyoto University, Kyoto, Japan; Case Medical Center, Cleveland, OH; University of Washington, Seattle, WA

Time: Saturday May 30, 8:00 AM to 11:30 AM
Location: S Hall A

Creating a national collaborative strategy to enhance trial accrual in NCI’s National Clinical Trials Network (NCTN) in the era of precision medicine.

Abstract No: 6589
Poster Board Number: Board #146

Author(s): Andrea Denicoff, Holly A Massett, Grace E. Mishkin, Rick Bangs, Jordan Berlin, Miriam B. Bischoff, Frank DeSanto, Anne Duli, Laura E. Horvath, Michael S. Katz, Ruth Lambersky, Bhupinder Singh Mann, Worta J. McCaskill-Stevens, Nita Seibel, Sharon Hartson Stine, Wade Williams, Margaret M. Mooney, Jeffrey S. Abrams; National Cancer Institute, Bethesda, MD; SWOG, San Antonio, TX; Vanderbilt-Ingram Cancer Center, Nashville, TN; Stanford Cancer Ctr, Stanford, CA; SWOG, Ann Arbor, MI; Case Comprehensive Cancer Center, Cleveland, OH; Alliance for Clinical Trials in Oncology, Naperville, IL; ECOG-ACRIN, North Hollywood, CA; ECOG-ACRIN, Philadelphia, PA; National Cancer Institute, Rockville, MD; NRG Oncology, Merchantville, NJ; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Time: Monday June 1, 1:15 PM to 4:45 PM
Location: S Hall A
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146.

Abstract No: 1082
Poster Board Number: Board #196
Author(s): Kathy Miller, Yan Tong, David R Jones, Tom Walsh, Michael A. Danso, Cynthia X. Ma, Paula Silverman, Mary-Claire King, Sunil S. Badve, Susan M. Perkins; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; University of Washington, Seattle, WA; Virginia Onc Assoc, Norfolk, VA; Washington Univ, St Louis, MO; University Hosps Case Medc Ctr, Cleveland, OH; Indiana Univ, Indianapolis, IN

Time: Saturday May 30, 8:00 AM to 11:30 AM
Location: S Hall A

A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS).

Abstract No: 10501
Author(s): William D. Tap, Robin L Jones, Bartosz Chmielowski, Anthony D. Elias, Douglas Adkins, Brian Andrew Van Tine, Mark Agulnik, Matthew M. Cooney, Michael B. Livingston, Gregory K. Pennock, Amy Qin, Ashwin Shahir, Robert L. Ilaria, Ilaria Conti, Jan Cosaert, Gary K. Schwartz; Memorial Sloan Kettering Cancer Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; UCLA Melanoma Sarcoma Program, Los Angeles, CA; University of Colorado Cancer Center, Aurora, CO; Washington University School of Medicine in St. Louis, St. Louis, MO; Northwestern University, Chicago, IL; University Hospitals Case Medical Center, Cleveland, OH; Carolinas HealthCare System, Charlotte, NC; Levine Cancer Institute, Charlotte, NC; Eli Lilly and Company, Bridgewater, NJ; Eli Lilly and Company, Erl Wood, United Kingdom; Eli Lilly and Company, Indianapolis, IN; Columbia University Medical Center, New York, NY

Time: Monday June 1, 3:00 PM to 6:00 PM
Location: S504

Phase I trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A Children’s Oncology Group Study.

Abstract No: 10036
Poster Board Number: Board #106
Author(s): Robin Elizabeth Norris, Elizabeth Fox, Joel M. Reid, Andrew T. Ralya, Xiaowei Liu, Charlotte H. Ahern, Charles Minard, Jodell Dahl, Rachel Eubank, Brenda Weigel; Rainbow Babies and Children's Hosp, Moreland Hills, OH; University of Philadelphia, Philadelphia, PA; Department of Oncology, Mayo Clinic, Rochester, MN; Mayo Clinic, Rochester, MN; Children's Oncology Group, Monrovia, CA; Baylor College of Medicine, Houston, TX; University of Minnesota Health, Minneapolis, MN; Children's National Medical Center, Washington D.C., DC; University of Minnesota, Minneapolis, MN

Type: Poster Session
Time: Sunday May 31, 8:00 AM to 11:30 AM